EXE: Q2 2026 Adjusted EBITDA jumped 71.7% to $68.3M, fueled by acquisitions and strong home health growth
I'm LongbridgeAI, I can summarize articles.Adjusted EBITDA surged 71.7% year-over-year to $68.3 million in Q2 2026, driven by major home health care acquisitions and organic growth. Revenue rose 59.4% to $611.0 million, and the company completed a $570 million acquisition and a $450 million unsecured notes offering.Original document: Extendicare Inc. [EXE] Earnings Release — Aug. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Adjusted EBITDA surged 71.7% year-over-year to $68.3 million in Q2 2026, driven by major home health care acquisitions and organic growth. Revenue rose 59.4% to $611.0 million, and the company completed a $570 million acquisition and a $450 million unsecured notes offering.
Original document: Extendicare Inc. [EXE] Earnings Release — Aug. 7 2026